Introduction

Advanced or metastatic prostate cancer is initially amenable to androgen deprivation therapy (ADT), but eventually escapes from the therapeutic pressures and evolves into castration-resistant prostate cancer (CRPC) [1]. The molecular mechanisms of adaptive resistance to ADT have been extensively studied to identify new therapeutic options [2, 3]. Various therapeutic agents against CRPC were approved [4, 5] or currently under evaluation in clinical trials [6]. However, there are still no effective therapeutic regimens available for CRPC. Therefore, the targetable molecules and pathways for biological vulnerability of CRPC are needed to be identified to develop novel promising therapeutic modalities.

Geraniol is an acyclic monoterpene alcohol that is found in essential oils of fruits and herbs [7]. Geraniol has been shown to exert a chemotherapeutic activity against various types of cancer, such as pancreas and colon cancer [8, 9, 10]. We have found that geraniol specifically suppresses the growth of prostate cancer in cultured cell and xenograft models.

Geraniol suppresses prostate cancer growth through down-regulation of E2F8

Sanghoon Lee1, Yu Rang Park2, Su-Hwa Kim3, Eun-Jung Park3, Min Ji Kang4, Insuk So3,5, Jung Nyeo Chun3,5 & Ju-Hong Jeon3,5

1Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, Utah 84112 5650
2Office of Clinical Research Information, Asan Medical Center, Seoul 05535, Korea
3Department of Physiology and Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Korea
4Department of Biomedical Sciences, University of Ulsan College of Medicine, Seoul 05535, Korea
5Institute of Human-Environment Interface Biology, Seoul National University, Seoul 03080, Korea

Keywords
Bioinformatics, cell cycle control, clustering analysis, E2F8, geraniol, master regulator analysis, prostate cancer

Abstract

Geraniol, an acyclic dietary monoterpene, has been found to suppress cancer survival and growth. However, the molecular mechanism underlying the anti-tumor action of geraniol has not been investigated at the genome-wide level. In this study, we analyzed the microarray data obtained from geraniol-treated prostate cancer cells. Geraniol potently altered a gene expression profile and primarily down-regulated cell cycle-related gene signatures, compared to linalool, another structurally similar monoterpene that induces no apparent phenotypic changes. Master regulator analysis using the prostate cancer-specific regulatory interactome identified that the transcription factor E2F8 as a specific target molecule regulates geraniol-specific cell cycle signatures. Subsequent experiments confirmed that geraniol down-regulated E2F8 expression and the knockdown of E2F8 was sufficient to suppress cell growth by inducing G2/M arrest. Epidemiological analysis showed that E2F8 is up-regulated in metastatic prostate cancer and associated with poor prognosis. These results indicate that E2F8 is a crucial transcription regulator controlling cell cycle and survival in prostate cancer cells. Therefore, our study provides insight into the role of E2F8 in prostate cancer biology and therapeutics.
tumor models [11, 12], compared to linalool, another structurally similar monoterpene that induce no apparent phenotype changes [12, 13]. These results suggest that geraniol can be exploited as chemical moiety for developing anticancer drugs or as a valuable chemical probe for dissecting complex biological processes, discovering hidden molecular relations, and identifying therapeutic target molecules and pathways. However, the molecular mechanisms by which geraniol induces the changes in cellular phenotypes have been little investigated, particularly at the genome-wide level.

In this study, we performed DNA microarray experiments to explore the molecular mechanisms of antitumor action of geraniol in prostate cancer cells. Through computational analyses, we identified that E2F8 is a target transcription factor of geraniol and the knockdown of E2F8 suppresses cell growth. In addition, we found that E2F8 is associated with poor survival of prostate cancer patients. Our findings provide insight into understanding the antitumor actions of geraniol, unraveling the role of E2F8 in CRPC biology, and developing novel therapeutic strategies.

Materials and Methods

Cell culture and microarray
PC-3 prostate cancer cells were treated with 1 mmol/L geraniol or linalool in 0.1% ethanol (vehicle) for 24 h and then DNA microarray experiments were performed as described in our previous study [14]. The microarray data are available through the Gene Expression Omnibus (GEO) database (accession number GSE45567). Rigorous data preprocessing for quality control and normalization were performed as described in our previous study [15]. The combined microarray data set contained 11,877 genes which were mapped from microarray probes using a custom mapping file from the BrainArray resource (version 14.0.0) (http://brainarray.mbi.uib.edu/brainarray/). The normalized data of 121 microarray samples were used for constructing PC-3 cell-specific interactome, which is available from GEO (GSE67157).

Unsupervised clustering analysis, internal cluster validation, and supervised classification
For the transcriptional subtyping of the microarray data, we performed unbiased clustering analysis in a uniform manner. We used an unsupervised feature selection method to determine 5000 genes of high variance across all microarray samples [16] and then performed cValid on the data of 5000 genes to measure an optimized clustering size using different clustering algorithms such as, Clustering LARge Applications (CLARA), hierarchical, k-means [17], and Partitioning Around Medoids (PAM) [18]. In cValid test, Dunn index for every cluster size each clustering algorithm was obtained to assess both intracluster homogeneity and intercluster separation by the ratio of the smallest distance between observations not in the same cluster to the largest intracluster distance [19]. The clusters were validated through principal component analysis (PCA). The first and second principal components in the PCA plot were used to calculate the sum of % variance, and average (λ) and standard deviation (σ) of the Euclidean distance (ED) between a medoid and a sample in each cluster. For supervised classification, Random Forest, which is an ensemble learning method for classification and regression, was used to validate the clusters [20].

SAM and GSEA
Significance analysis of microarrays (SAM) analysis was used to identify differentially expressed genes (DEGs) out of the 5000 genes among the clusters. A tuning parameter, delta of 0.4, optimized the cutoff for significance with the estimation of false discovery rate (FDR) threshold q-value of 0.01. GSEA (gene set enrichment analysis) using geraniol-specific DEGs was performed to obtain biological interpretation of gene signatures, and visualized mutually enriched gene signatures using EnrichmentMap [21].

Prostate cancer-specific interaction network and MRA
ARACNe algorithm [22] was used to reconstruct prostate cancer-specific transcriptional interactome as previously described [15] with a few modifications. The 5000 genes of high variance in the microarray data and transcription factors (TFs) were used to infer the direct interactions among TFs and their regulons. We updated the list of human TFs from Animal Transcription Factor Database (AnimalTFDB) [23] and transcriptional regulatory gene signatures of Gene Ontology (GO), which are registered in MsigDB 4.0 [24], such as REGULATION_OF_TRANSCRIPTION (GO:0045449) and TRANSCRIPTION_FACTOR_ACTIVITY (GO:003700). MRA-Fisher’s exact test (FET) [25] and MAster Regulator INFerence algorithm (MARINa) [26] were used to infer master regulator candidates and their targets in prostate cancer interactome. The ARACNe preprocessing and MRA-FET analysis were run in geWorkbench software. MARINa results were visualized by geWorkbench version 2.6.0 (http://www.geworkbench.org) [27].

Biomedical data analysis
We analyzed the microarray data sets of prostate cancer patients, GSE21034 [28] and GSE3325 [29], to examine E2F8 expression levels in different prostate cancer stages.
using ANOVA test. After normalization as described in our previous study [14], Affymetrix probe sets were mapped to Entrez Gene IDs using custom mapping files from the BrainArray resource (version 17.1.0). Then, the data sets of GSE21034 and GSE3325 were combined by overlapping genes and went through batch adjusting. Statistical analysis and data processing were performed using R (version 3.1.2) (https://www.r-project.org/) [30]. The nonparametric Kaplan–Meier method was employed to obtain survival curves and the log-rank test was used to determine overall survival from the International Cancer Genome Consortium (ICGC) dataset as previously described [31]. For these analyses, \( P = 0.05 \) was considered significant.

**Results**

**Geraniol induces a distinctive gene expression profile**

We have previously shown that geraniol specifically suppresses cell survival and growth in PC-3 cells, compared to linalool [11]. To better understand the mechanism of action of geraniol, we compared gene expression profiles using the microarray data (GSE45567) obtained from vehicle-, linalool-, and geraniol-treated PC-3 cells. Our scheme for computational analyses is described in Figure S1. Hierarchical clustering algorithm clustered the microarray samples with whole 11,877 genes into three distinct groups (Fig. 1). These results indicate that geraniol induces the distinctive changes in gene expression, compared to linalool.

We then selected 5000 genes of the high variance across the nine samples, and confirmed that they still represent the same hierarchical clustering as Figure 1 (Fig. S2A). An optimal cluster size was estimated by clValid algorithm in various unsupervised clustering algorithms to assess cluster stability. clValid predicted that the cluster size 2 would be the most dependable by every clustering algorithm with the maximum Dunn index of 1.17 (Table S1). For validation, CLARA identified that vehicle- and linalool-treated samples constructed one cluster and geraniol-treated samples constituted another cluster by ED metric. However, internal validation by PCA and supervised classification by Random Forest showed that vehicle-, linalool-, and geraniol-treated samples can be separated into independent clusters, supporting the hierarchical clustering analysis (Fig. S2B and Table S2). These findings reaffirm that geraniol induces a unique gene expression profile change.

**Geraniol regulates cell cycle gene signatures**

SAM analysis revealed that geraniol specifically affected the expression levels of 2527 genes in PC-3 cells (Fig. 2A).

---

**Statistical analysis**

The comparison of the means among experimental groups was performed using one-way ANOVA (Bonferroni’s multiple comparison test) followed by a post hoc test. For these analyses, \( P = 0.05 \) was considered significant.
Using these genes, we examined the effect of geraniol on GO biological process. GSEA identified 25 down-regulated and 3 up-regulated gene signatures with q-value 0.2 (Table S3). Of the 28 gene signatures, 13 signatures were associated with cell cycle or proliferation and 8 cell cycle-related signatures were placed on the top with small normalized enrichment score (NES) values (indicated by blue in Table S3). The network visualization of enriched GO terms also showed that the geraniol primarily down-regulates cell cycle- or proliferation-related gene signatures (Fig. 2B). To confirm these computational findings, we analyzed cell cycle profile. Geraniol increased G2/M phase, which is more evident in thymidine-nocodazole block experiments (Fig. 2C). Geraniol prevented the cell relief from nocodazole block.

E2F8 is identified as a master regulator in prostate cancer

We found 79 leading edge subset (LES) genes (Table S4) overlapping across the 13 cell cycle-related signatures and denoted them as geraniol-specific cell cycle signatures for MRA. We then investigated the transcriptional regulatory mechanisms that determine the geraniol-specific cell cycle signatures. ARACNe inferred a small consensus network of 161,446 interactions from the 462 human TF hub markers and the 5000 genes of high variance. From this transcriptional interactome, the MRA algorithm identified 40 TFs as master regulator (MR) candidates that down-regulate geraniol-specific cell cycle signatures. In addition, the MARINa algorithm inferred 224 TFs as MR candidates that differentiate the geraniol cluster from the vehicle one (Table S5): the 71 MRs out of 226 were negatively enriched and 153 MRs were positively enriched in the geraniol cluster.

We then found that 28 MRs are commonly found in both the MRA and the MARINa algorithms (Fig. 3A and Table 1). The gene expression levels of 28 MRs were markedly altered in the geraniol cluster (heatmap in Fig. 3B) and correlated with those of their target genes (red bars in Fig. 3B). Of the 28 MRs, E2F8 as
a top inactivated MR in the geraniol cluster was identified to regulate 58 target genes in the geraniol-specific cell cycle signature genes (Table S6 and Fig. S3). Out of the 58 target genes, 18 genes are involved in G$_2$/M phase cell cycle process according to molecular signature database (indicated in bold in Table S6). Indeed, geraniol specifically reduced the expression of E2F8 at both mRNA and protein levels in PC-3, compared to linalool (Figs. 3C and S6). We also obtained the comparable results from LNCaP prostate cancer cells (Fig. 3C). In addition, we identified that geraniol regulated the expression levels of other several master regulators (Fig. S4).

**E2F8 knockdown induces G$_2$/M arrest**

To assess the role of E2F8 in geraniol-induced phenotypic changes, rescue experiments were performed. We found that E2F8 overexpression reversed geraniol-induced G$_2$/M arrest (Fig. 4). We then knocked down the level of E2F8 using siRNA against E2F8 (siE2F8). We first tested three different siE2F8s in PC-3 cells. All tested siE2F8s suppressed cell growth and induced G$_2$/M arrest (Fig. S5), excluding the off-target effect of siRNAs. Because siE2F8-1 was more effective than other siE2F8s, we chose siE2F8-1 in following studies.

We examined the effect of siE2F8-1 on cell cycle profile in PC-3 and LNCaP cells. MTT assays showed that E2F8 knockdown suppressed cell growth (Fig. 5A and D). In addition, siE2F8-1 markedly increased cell populations in the G$_2$/M phase (Fig. 5B and E) and induced the changes in the levels of cyclin A, cyclin B1, phospho-CDK2, and phospho-histone H3, which are G$_2$/M transition regulatory proteins (Fig. 5C and F). These results indicate that E2F8 knockdown substantially reproduces geraniol-induced G$_2$/M arrest phenotype. In addition, our findings suggest that E2F8 plays a crucial role in the regulation of G$_2$/M cell cycle in prostate cancer cells.
### Table 1. List of 28 master regulators that control geraniol-specific cell cycle signatures.

| Gene ID | Gene symbol | Gene description | FET P-Value\(^1\) | Markers in regulon\(^2\) | Markers in intersection set\(^3\) | Mode\(^4\) | Odds Ratio\(^5\) | NES\(^6\) | absNES | Fold Change\(^7\) | q-value\(^7\) |
|---------|-------------|------------------|-------------------|---------------------------|---------------------------|-----------|-----------------|-------|-------|-----------------|----------|
| 79733   | E2F8        | E2F transcription factor 8 | 3.31E-43          | 478                        | 58                         | —         | 15.00           | -13.72 | 13.72 | 0.66            | 0.00     |
| 4605    | MYBL2       | V-myc myeloblastosis viral oncogene homolog-like 2 | 9.02E-30          | 539                        | 50                         | —         | 15.77           | -13.79 | 13.79 | 0.68            | 0.00     |
| 2146    | EZH2        | Enhancer of zeste homolog 2 (Drosophila) | 7.32E-24          | 578                        | 46                         | —         | 12.25           | -14.68 | 14.68 | 0.73            | 0.00     |
| 1063t   | CENPF       | Centromere protein F, 350/400 kDa (mitosin) | 1.75E-21          | 493                        | 41                         | —         | 16.32           | -12.51 | 12.51 | 0.56            | 0.00     |
| 3148    | HMGB2       | High mobility group box 2 | 3.34E-20          | 501                        | 40                         | —         | 8.74            | -12.44 | 12.44 | 0.63            | 0.00     |
| 3149t   | HMGB3       | High mobility group box 3 | 6.28E-24          | 400                        | 40                         | —         | 16.41           | -11.34 | 11.34 | 0.75            | 0.00     |
| 8914    | TIMELESS    | Timeless homolog (Drosophila) | 1.04E-21          | 457                        | 40                         | —         | 10.64           | -12.38 | 12.38 | 0.83            | 0.00     |
| 865     | CBFB        | Core-binding factor, beta subunit | 8.91E-15          | 597                        | 37                         | —         | 9.97            | -13.25 | 13.25 | 0.85            | 0.01     |
| 8607    | RUVBL1      | RuvB-like 1 (E. coli) | 1.29E-11          | 751                        | 37                         | —         | 9.14            | -13.41 | 13.41 | 0.73            | 0.00     |
| 11137   | PWP1        | PWP1 homolog (S. cerevisiae) | 1.47E-14          | 571                        | 36                         | —         | 6.98            | -12.81 | 12.81 | 0.90            | 0.24     |
| 2305    | FOXM1       | Forkhead box M1 | 2.07E-15          | 504                        | 35                         | —         | 11.99           | -13.21 | 13.21 | 0.69            | 0.00     |
| 9232    | PTTG1       | Pituitary tumor-transforming 1 | 2.52E-15          | 475                        | 34                         | —         | 10.12           | -12.19 | 12.19 | 0.54            | 0.00     |
| 4602    | MYB         | V-myc myeloblastosis viral oncogene homolog | 4.96E-14          | 524                        | 34                         | —         | 11.80           | -11.35 | 11.35 | 0.62            | 0.00     |
| 7468    | WHSC1       | Wolf-Hirschhorn syndrome candidate 1 | 9.73E-12          | 590                        | 33                         | —         | 9.17            | -13.29 | 13.29 | 0.77            | 0.00     |
| 9735    | KNTC1       | Kinetochore associated 1 | 2.44E-16          | 354                        | 31                         | —         | 10.77           | -10.71 | 10.71 | 0.70            | 0.00     |
| 10856   | RUVBL2      | RuvB-like 2 (E. coli) | 4.11E-12          | 502                        | 31                         | —         | 8.55            | -11.67 | 11.67 | 0.83            | 0.00     |
| 4603    | MYBL1       | V-myc myeloblastosis viral oncogene homolog-like 1 | 4.01E-14          | 336                        | 28                         | —         | 11.84           | -10.73 | 10.73 | 0.76            | 0.00     |
| 2130    | EWSR1       | Ewing sarcoma breakpoint region 1 | 5.32E-13          | 372                        | 28                         | —         | 12.31           | -8.79  | 8.79  | 0.82            | 0.00     |
| 5252    | PHF1        | PHD finger protein 1 | 1.46E-10          | 468                        | 28                         | +         | 7.60            | 11.45  | 11.45 | 1.16            | 0.02     |
| 10849   | CD3EAP      | CD3e molecule, epsilon-associated protein | 3.76E-11          | 378                        | 26                         | —         | 17.60           | -11.50 | 11.50 | 0.79            | 0.00     |
| 221037  | JMJ1D1C     | Jumonji domain containing 1C | 1.08E-08          | 453                        | 25                         | +         | 19.28           | 9.36   | 9.36  | 1.32            | 0.00     |
| 7020    | TFAP2A      | Transcription factor AP-2 alpha | 4.85E-10          | 359                        | 24                         | +         | 5.16            | 6.01   | 6.01  | 1.23            | 0.00     |
| 10042   | HMGBX4      | HMGB box domain containing 4 | 1.86E-05          | 582                        | 23                         | —         | 7.59            | -10.37 | 10.37 | 0.76            | 0.00     |
| 5036    | PA2G4       | Proliferation-associated 2G4, 38 kDa | 2.06E-08          | 364                        | 22                         | —         | 14.26           | -11.18 | 11.18 | 0.82            | 0.00     |
| 9569    | GTF2RD1     | GTF2I repeat domain containing 1 | 1.07E-07          | 331                        | 20                         | +         | 6.67            | 7.26   | 7.26  | 1.19            | 0.01     |
| 7027    | TDP1        | Transcription factor Op-1 | 2.12E-06          | 398                        | 20                         | —         | 15.56           | -11.73 | 11.73 | 0.70            | 0.00     |
| 86      | ACTL6A      | Actin-like 6A | 1.55E-06          | 287                        | 17                         | —         | 7.17            | -3.26  | 3.26  | 0.76            | 0.00     |

(Continued)
Clinical relevance of E2F8 in prostate cancer

To address the clinical relevance of our findings, we examined the expression levels of E2F8 using microarray datasets of prostate cancer patients (GSE21034 and GSE3325) [28, 29]. The averages of normalized E2F8 expression levels were calculated from benign, primary, and metastatic tumor samples; its relative expression levels were -0.054, -0.025, and 0.146, respectively (ANOVA test, \( P = 3.44 \times 10^{-12} \); Fig. 6A). This result suggests that the increased expression of E2F8 is associated with prostate cancer metastasis. To assess the effect of E2F8 on clinical outcome, we compared overall survival in the prostate cancer patients with low- and high-expression of E2F8. Kaplan–Meier analysis indicated that the patients with high expression of E2F8 had significantly worse overall survival than those with low expression (HR = 2.912 and log-rank test \( P = 0.048 \)) (Fig. 6B).

Discussion

In this study, we described four main findings: (1) geraniol specifically induces the changes in cell cycle gene signatures; (2) geraniol reduces the expression levels of the transcription factor E2F8; (3) E2F8 controls G2/M cell cycle progression; and (4) E2F8 is up-regulated in metastatic prostate cancer and associated with worse survival in prostate cancer patients.

We have found that geraniol can be a useful chemical probe for dissecting the complicated phenotypes of prostate cancer and identifying therapeutic target molecules [10, 11]. In this study, we performed clustering analysis, pathway-based approach, and master regulator analysis using the microarray data and identified E2F8 as a target TF of geraniol. E2F8 is a member of atypical E2F family that regulates cell survival and embryonic development [35]. However, it is unclear whether E2F8 functions as a transcriptional repressor or activator [36, 37]. Emerging evidence suggests that E2F8 contributes to the oncogenic potentials of several types of cancer, such as hepatic or lung cancer [30, 31]. Our study reveals that E2F8 exerts pro-oncogenic activity in prostate cancer via G2/M cell cycle regulation.

Our results indicate that E2F8 is required for the growth of prostate cancer cells and is aberrantly expressed in metastatic prostate cancer. In addition, we demonstrate
that the overexpression of E2F8 has clinically relevant prognostic significance in prostate cancer. Therefore, these findings suggest that E2F8 is a novel targetable molecule for treatment of metastatic prostate cancer or CRPC patients. Our results provide a basis for future investigations aiming at elucidating the molecular mechanisms underlying the expression or activity of E2F8 in prostate cancer, which assists to understand the role of E2F8 in

Figure 5. E2F8 knockdown induces G2/M arrest and apoptosis. PC-3 (A–C) or LNCaP (D–F) cells were transfected with 100 nmol/L siE2F8 for the indicated times prior to MTT assay (A and D), cell cycle analysis (B and E), and western blot analysis (C and F). Cell growth was expressed as a relative value compared to that of siGFP as a control which was set to 100%. The data were expressed as the mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.005.

Figure 6. Clinical relevance of E2F8 in prostate cancer patients. (A) The expression levels of E2F8 in prostate cancer patient samples (GSE21034 and GSE3325) were represented in the box-plot. The x-axis indicates three different stages of prostate cancer and y-axis represents the normalized expression level of E2F8. (B) Survival curve for prostate cancer patients (ICGC dataset) based on the expression levels of E2F8. HR, hazard ratio (95% confidence interval).
CRPC biology and to develop novel cell cycle-targeted therapeutic strategies.

Acknowledgment

We thank Dr. Kenneth Smith of the Joint Centers for Systems Biology at Columbia University for helpful discussion on ARACNe and MRA analysis. This research was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2014R1A2A1A11050616), the Education and Research Encouragement Fund of Seoul National University Hospital (0320160010), and the Brain Korea 21 PLUS program.

Conflict of Interest

We hereby declare that we have no pecuniary or other personal interest, direct or indirect, in any matter that raises a conflict.

References

1. Karantanos, T., P. Corn, and T. Thompson. 2013. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32:5501–5511.
2. Wyatt, A. W., and M. E. Gleave. 2015. Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol. Med. 7:878–894.
3. Katsogiannou, M., H. Ziouziou, S. Karaki, C. Andrieu, M. Henry de Villeneuve, and P. Rocchi. 2015. The hallmarks of castration-resistant prostate cancers. Cancer Treat. Rev. 41:588–597.
4. Basch, E., D. A. Loblaw, T. K. Oliver, M. Carducci, R. C. Chen, J. N. Frame, et al. 2014. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J. Clin. Oncol. 32:3436–3448.
5. Chandrasekar, T., J. C. Yang, A. C. Gao, and C. P. Evans. 2015. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 13:206–215.
6. Suzman, D. L., and E. S. Antonarakis. 2014. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther. Adv. Med. Oncol. 6:167–179.
7. Łapczynski, A., S. P. Bhatia, R. J. Foxenberg, C. S. Letizia, and A. M. Api. 2008. Fragrance material review on geraniol. Food Chem. Toxicol. 46(Suppl 11):S60–S170.
8. Cho, M., I. So, J. N. Chun, and J. H. Jeon. 2016. The antitumor effects of geraniol: modulation of cancer hallmark pathways (Review). Int. J. Oncol. 48:1772–1782.
9. Bardon, S., V. Foussard, S. Fournel, and A. Loubat. 2002. Monoterpenes inhibit proliferation of human colon cancer cells by modulating cell cycle-related protein expression. Cancer Lett. 181:187–194.
10. Wiseman, D. A., S. R. Werner, and P. L. Crowell. 2007. Cell cycle arrest by the isoprenoids perillyl alcohol, geraniol, and farnesol is mediated by p21(Cip1) and p27(Kip1) in human pancreatic adenocarcinoma cells. J. Pharmacol. Exp. Ther. 320:1163–1170.
11. Kim, S.-H., H. C. Bae, E.-J. Park, C. R. Lee, B.-J. Kim, S. Lee, et al. 2011. Geraniol inhibits prostate cancer growth by targeting cell cycle and apoptosis pathways. Biochem. Biophy. Res. Commun. 407:129–134.
12. Kim, S.-H., E.-J. Park, C. R. Lee, J. N. Chun, N.-H. Cho, I.-G. Kim, et al. 2012. Geraniol induces cooperative interaction of apoptosis and autophagy to elicit cell death in PC-3 prostate cancer cells. Int. J. Oncol. 40:1683–1690.
13. Crowell, P. L. 1999. Prevention and therapy of cancer by dietary monoterpenes. The Journal of nutrition 129:775S–778S.
14. Kim, S.-H., S. Lee, S. R. Piccolo, K. Allen-Brady, E.-J. Park, J. N. Chun, et al. 2012. Menthol induces cell-cycle arrest in PC-3 cells by down-regulating G2/M genes, including polo-like kinase 1. Biochem. Biophy. Res. Commun. 422:436–441.
15. Lee, S., J. N. Chun, S.-H. Kim, I. So, and J.-H. Jeon. 2013. Icilin inhibits E2F1-mediated cell cycle regulatory programs in prostate cancer. Biochem. Biophy. Res. Commun. 29:1005–1010.
16. van der Laan, M. J., and K. S. Pollard. 2003. A new algorithm for hybrid hierarchical clustering with visualization and the bootstrap. J Stat Plan Inference 117:275–303.
17. Hartigan, J. A., and M. A. Wong. 1979. Algorithm AS 136: a k-means clustering algorithm. Appl. Stat. 28:100–108.
18. Ouellet, V., S. M. Labbe, D. P. Blondin, S. Phoenix, B. Guerin, F. Haman, et al. 2012. Brown adipose tissue oxidative metabolism contributes to energy expenditure during acute cold exposure in humans. J Clin Invest 122:545–552.
19. Brock, G., V. Pihur, S. Datta, and S. Datta. 2008. clValid, an R package for cluster validation. J. Stat. Softw. 25:1–22.
20. Breiman, L. 2001. Random forests. Mach. Learn 45:5–32.
21. Merico, D., R. Isserlin, O. Stueker, A. Emili, and G. D. Bader. 2010. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS ONE 5:e13984.
22. Margolin, A. A., I. Nemenman, K. Basso, C. Wiggins, G. Stolovitzky, R. D. Faver, et al. 2006. ARACNe: an algorithm for the reconstruction of gene regulatory
networks in a mammalian cellular context. BMC Bioinformatics 7:S7.
23. Zhang, H.-M., H. Chen, W. Liu, H. Liu, J. Gong, H. Wang, et al. 2012. AnimalTFDB: a comprehensive animal transcription factor database. Nucleic Acids Res. 40:D144–D149.
24. Liberzon, A., A. Subramanian, R. Pinchback, H. Thorvaldsdóttir, P. Tamayo, and J. P. Mesirov. 2011. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27:1739–1740.
25. Lefebvre, C., P. Rajbhandari, M. J. Alvarez, P. Bandaru, W. K. Lim, M. Sato, et al. 2010. A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinatal centers. Mol. Syst. Biol. 6:377–386.
26. Lim, W. K., E. Lyashenko, and A. Califano: Master regulators used as breast cancer metastasis classifier Pacific Symposium on Biocomputing. 2009:504-15.
27. Floratos, A., K. Smith, Z. Ji, J. Watkinson, and A. Califano. 2010. geWorkbench: an open source platform for integrative genomics. Bioinformatics 26:1779–1780.
28. Taylor, B. S., N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao, B. S. Carver, et al. 2010. Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11–22.
29. Varambally, S., J. Yu, B. Laxman, D. R. Rhodes, R. Mehra, S. A. Tomlins, et al. 2005. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8:393–406.
30. Team RC. 2005. R: A language and environment for statistical computing. R foundation for Statistical Computing 2005.
31. Park, Y. R., J. N. Chun, I. So, H. J. Kim, S. Baek, J. H. Jeon, et al. 2016. Data-driven analysis of TRP channels in cancer: linking variation in gene expression to clinical significance. Cancer Genom Proteom 13:83–90.
32. Deng, Q., Q. Wang, W.-Y. Zong, D.-L. Zheng, Y.-X. Wen, K.-S. Wang, et al. 2010. E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation. Cancer Res. 70:782–791.
33. Zalmas, L. P., X. Zhao, A. L. Graham, R. Fisher, C. Reilly, A. S. Coutts, et al. 2008. DNA-damage response control of E2F7 and E2F8. EMBO Rep. 9:252–259.
34. Wang, H., C. Zhang, A. Rorick, D. Wu, M. Chiu, J. Thomas-Ahner, et al. 2011. CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability. Cancer Res. 71:4866–4876.
35. Li, J., C. Ran, E. Li, F. Gordon, G. Comstock, H. Siddiqui, et al. 2008. Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. Dev. Cell 14:62–75.
36. Lammens, T., J. Li, G. Leone, and L. De Veylder. 2009. Atypical E2Fs: new players in the E2F transcription factor family. Trends Cell Biol. 19:111–118.
37. Park, S. A., J. Platt, J. W. Lee, F. Lopez-Giraldez, R. S. Herbst, and J. S. Koo. 2015. E2F8 as a novel therapeutic target for lung cancer. J. Natl Cancer Inst. 107:djv151–djv156.

Supporting Information

Additional supporting information may be found in the online version of this article:

- **Figure S1.** Schematic diagram for the computational approaches.
- **Figure S2.** Gene expression profiles and PCA plot.
- **Figure S3.** Gene expression of E2F8 target genes across three clusters.
- **Figure S4.** The expression levels of master regulators.
- **Figure S5.** The effect of siRNAs against E2F8 on cell growth and cell cycle.
- **Figure S6.** Full scan images of used in this study.
- **Table S1.** Summary of Dunn index in the different cluster size by clValid analysis.
- **Table S2.** Classification of monoterpenic-treated PC3 cell microarray samples by Random Forest.
- **Table S3.** List of 28 gene signatures of Gene Ontology Biological Process in the geraniol cluster.
- **Table S4.** List of 79 LES genes that cover all of the LES genes from cell cycle and proliferation gene signatures.
- **Table S5.** The result of MARINa analysis: 224 TFs that were activated or inactive in the geraniol cluster.
- **Table S6.** List of 58 target genes of E2F8.